This can lead to reduced caloric intake without extreme restriction or hunger-driven relapse
Benzphetamine, diethylpropion, phendimetrazine, phentermine, topiramate, bupropion, naltrexone, locaserin, and fenfluramine, among others, will not be approved
GHK-Cu is stable, non-irritating and acts on a broader genomic spectrum
Interestingly, the treatment demonstrated dose-dependent therapeutic effects, with moderate dosages proving more effective than high doses (1,000 mg/kg), possibly due to pharmacodynamic principles, where excessive concentrations saturate biological pathways and diminish therapeutic outcomes (Tyagi et al., 2025
If the side effects persist, your health care provider may prescribe a different medication that supports blood sugar control and weight loss